Tags

Type your tag names separated by a space and hit enter

Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
Life Sci. 1998; 63(10):PL137-43.LS

Abstract

We evaluated the effects of FR901533, endothelin converting enzyme inhibitor, on development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Pulmonary hypertension was induced by a single injection of monocrotaline (80 mg/kg). Twenty-four hours later (day 1), continuous subcutaneous injection of FR901533 (100 mg/kg/day) was started. Right ventricular systolic pressure, mass ratio of right ventricle to left ventricle, right ventricular wall thickness, right ventricular myocardial fiber diameter, percent medial thickness, and percent smooth muscle area in pulmonary arteries were significantly less in rats that received FR901533 than in the control with monocrotaline on day 28. Both immunoreactivities of endothelin-1 in pulmonary arteries and plasma endothelin-1 levels were observed significantly less in rats treated with FR901533 than in the control with monocrotaline. There were significant increased immunoreactivities of endothelin-B receptor in pulmonary arteries in rats that received FR901533 as compared with those in the control with monocrotaline. FR901533 (100 mg/kg/day), protected the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.

Authors+Show Affiliations

Department of Infectious Diseases, Institute of Medical Science, University of Tokyo, Japan. takahata@ims.u-tokyo.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9734710

Citation

Takahashi, T, et al. "Endothelin Converting Enzyme Inhibitor Protects Development of Right Ventricular Overload and Medial Thickening of Pulmonary Arteries in Rats With Monocrotaline-induced Pulmonary Hypertension." Life Sciences, vol. 63, no. 10, 1998, pp. PL137-43.
Takahashi T, Kanda T, Inoue M, et al. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci. 1998;63(10):PL137-43.
Takahashi, T., Kanda, T., Inoue, M., Sumino, H., Kobayashi, I., Iwamoto, A., & Nagai, R. (1998). Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sciences, 63(10), PL137-43.
Takahashi T, et al. Endothelin Converting Enzyme Inhibitor Protects Development of Right Ventricular Overload and Medial Thickening of Pulmonary Arteries in Rats With Monocrotaline-induced Pulmonary Hypertension. Life Sci. 1998;63(10):PL137-43. PubMed PMID: 9734710.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. AU - Takahashi,T, AU - Kanda,T, AU - Inoue,M, AU - Sumino,H, AU - Kobayashi,I, AU - Iwamoto,A, AU - Nagai,R, PY - 1998/9/12/pubmed PY - 1998/9/12/medline PY - 1998/9/12/entrez SP - PL137 EP - 43 JF - Life sciences JO - Life Sci VL - 63 IS - 10 N2 - We evaluated the effects of FR901533, endothelin converting enzyme inhibitor, on development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Pulmonary hypertension was induced by a single injection of monocrotaline (80 mg/kg). Twenty-four hours later (day 1), continuous subcutaneous injection of FR901533 (100 mg/kg/day) was started. Right ventricular systolic pressure, mass ratio of right ventricle to left ventricle, right ventricular wall thickness, right ventricular myocardial fiber diameter, percent medial thickness, and percent smooth muscle area in pulmonary arteries were significantly less in rats that received FR901533 than in the control with monocrotaline on day 28. Both immunoreactivities of endothelin-1 in pulmonary arteries and plasma endothelin-1 levels were observed significantly less in rats treated with FR901533 than in the control with monocrotaline. There were significant increased immunoreactivities of endothelin-B receptor in pulmonary arteries in rats that received FR901533 as compared with those in the control with monocrotaline. FR901533 (100 mg/kg/day), protected the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. SN - 0024-3205 UR - https://www.unboundmedicine.com/medline/citation/9734710/Endothelin_converting_enzyme_inhibitor_protects_development_of_right_ventricular_overload_and_medial_thickening_of_pulmonary_arteries_in_rats_with_monocrotaline_induced_pulmonary_hypertension_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0024-3205(98)00347-6 DB - PRIME DP - Unbound Medicine ER -